Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 21

1.

Organ-specific expression of the colon cancer antigen A33, a cell surface target for antibody-based therapy.

Garinchesa P, Sakamoto J, Welt S, Real F, Rettig W, Old L.

Int J Oncol. 1996 Sep;9(3):465-71.

PMID:
21541536
2.

Biodistribution of 211At-labeled humanized monoclonal antibody A33.

Almqvist Y, Steffen AC, Lundqvist H, Jensen H, Tolmachev V, Sundin A.

Cancer Biother Radiopharm. 2007 Aug;22(4):480-7.

PMID:
17803442
3.

In vitro and in vivo characterization of 177Lu-huA33: a radioimmunoconjugate against colorectal cancer.

Almqvist Y, Steffen AC, Tolmachev V, Divgi CR, Sundin A.

Nucl Med Biol. 2006 Nov;33(8):991-8.

PMID:
17127172
4.

A phase I radioimmunolocalization trial of humanized monoclonal antibody huA33 in patients with gastric carcinoma.

Sakamoto J, Oriuchi N, Mochiki E, Asao T, Scott AM, Hoffman EW, Jungbluth AA, Matsui T, Lee FT, Papenfuss A, Kuwano H, Takahashi T, Endo K, Old LJ.

Cancer Sci. 2006 Nov;97(11):1248-54.

5.

Cellular processing in the SW1222 cell line of mAb A33 directly and indirectly radiohalogenated.

Höglund J, Orlova A, Sundin A, Lundqvist H, Tolmachev V.

Oncol Rep. 2006 Jul;16(1):159-63.

PMID:
16786140
6.

Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma.

Chong G, Lee FT, Hopkins W, Tebbutt N, Cebon JS, Mountain AJ, Chappell B, Papenfuss A, Schleyer P, U P, Murphy R, Wirth V, Smyth FE, Potasz N, Poon A, Davis ID, Saunder T, O'keefe GJ, Burgess AW, Hoffman EW, Old LJ, Scott AM.

Clin Cancer Res. 2005 Jul 1;11(13):4818-26.

7.

A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake.

Scott AM, Lee FT, Jones R, Hopkins W, MacGregor D, Cebon JS, Hannah A, Chong G, U P, Papenfuss A, Rigopoulos A, Sturrock S, Murphy R, Wirth V, Murone C, Smyth FE, Knight S, Welt S, Ritter G, Richards E, Nice EC, Burgess AW, Old LJ.

Clin Cancer Res. 2005 Jul 1;11(13):4810-7.

8.

Preparation of iodine-131 labelled human growth hormone of high specific activity.

HUNTER WM, GREENWOOD FC.

Nature. 1962 May 5;194:495-6. No abstract available.

PMID:
14450081
9.

Phase I study of anticolon cancer humanized antibody A33.

Welt S, Ritter G, Williams C Jr, Cohen LS, John M, Jungbluth A, Richards EA, Old LJ, Kemeny NE.

Clin Cancer Res. 2003 Apr;9(4):1338-46.

10.

Immuno-PET of human colon xenograft- bearing BALB/c nude mice using 124I-CDR-grafted humanized A33 monoclonal antibody.

Lee FT, Hall C, Rigopoulos A, Zweit J, Pathmaraj K, O'Keefe GJ, Smyth FE, Welt S, Old LJ, Scott AM.

J Nucl Med. 2001 May;42(5):764-9.

11.

Rapid and specific targeting of monoclonal antibody A33 to a colon cancer xenograft in nude mice.

Barendswaard EC, Scott AM, Divgi CR, Williams C Jr, Coplan K, Riedel E, Yao TJ, Gansow OA, Finn RD, Larson SM, Old LJ, Welt S.

Int J Oncol. 1998 Jan;12(1):45-53.

PMID:
9454885
12.

Antibody-based immunological therapies.

Scott AM, Welt S.

Curr Opin Immunol. 1997 Oct;9(5):717-22. Review.

PMID:
9368782
13.

Kinetic analysis of the interaction between the monoclonal antibody A33 and its colonic epithelial antigen by the use of an optical biosensor. A comparison of immobilisation strategies.

Catimel B, Nerrie M, Lee FT, Scott AM, Ritter G, Welt S, Old LJ, Burgess AW, Nice EC.

J Chromatogr A. 1997 Jul 25;776(1):15-30.

PMID:
9286074
14.

Characterization of posttranslational modifications of human A33 antigen, a novel palmitoylated surface glycoprotein of human gastrointestinal epithelium.

Ritter G, Cohen LS, Nice EC, Catimel B, Burgess AW, Moritz RL, Ji H, Heath JK, White SJ, Welt S, Old LJ, Simpson RJ.

Biochem Biophys Res Commun. 1997 Jul 30;236(3):682-6.

PMID:
9245713
15.

Enhanced antitumor activity of combination radioimmunotherapy (131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil).

Tschmelitsch J, Barendswaard E, Williams C Jr, Yao TJ, Cohen AM, Old LJ, Welt S.

Cancer Res. 1997 Jun 1;57(11):2181-6.

16.

The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily.

Heath JK, White SJ, Johnstone CN, Catimel B, Simpson RJ, Moritz RL, Tu GF, Ji H, Whitehead RH, Groenen LC, Scott AM, Ritter G, Cohen L, Welt S, Old LJ, Nice EC, Burgess AW.

Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):469-74.

17.

Enhancement of radiation dose to the nucleus by vesicular internalization of iodine-125-labeled A33 monoclonal antibody.

Daghighian F, Barendswaard E, Welt S, Humm J, Scott A, Willingham MC, McGuffie E, Old LJ, Larson SM.

J Nucl Med. 1996 Jun;37(6):1052-7.

18.

Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer.

Welt S, Scott AM, Divgi CR, Kemeny NE, Finn RD, Daghighian F, Germain JS, Richards EC, Larson SM, Old LJ.

J Clin Oncol. 1996 Jun;14(6):1787-97.

PMID:
8656247
19.

Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy.

King DJ, Antoniw P, Owens RJ, Adair JR, Haines AM, Farnsworth AP, Finney H, Lawson AD, Lyons A, Baker TS, et al.

Br J Cancer. 1995 Dec;72(6):1364-72.

20.

Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer.

Welt S, Divgi CR, Kemeny N, Finn RD, Scott AM, Graham M, Germain JS, Richards EC, Larson SM, Oettgen HF, et al.

J Clin Oncol. 1994 Aug;12(8):1561-71.

PMID:
8040668

Supplemental Content

Support Center